BridgeBio Pharma, Inc. Contractual Obligation
BridgeBio Pharma, Inc. (BBIO) had Contractual Obligation of $2.03 billion as of 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligation · last filed 2025-08-05
- 2025-06-30: Contractual Obligation $2.03B.
| Period end | Contractual Obligation |
|---|---|
| 2025-06-30 | $2.03B 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |